期刊文献+

干细胞表面标志物CD133在胃癌中的研究进展 被引量:7

Progress of stem cell surface marker CD133 in gastric cancer
原文传递
导出
摘要 胃癌的发病率和病死率在我国各种恶性肿瘤中均居于首位,其早期诊断率低,患者预后差。CD133分子在胃癌组织的表达量显著高于癌旁正常组织,并与肿瘤大小、淋巴结转移及预后有关。同时,CD133阳性表达可能还与胃癌新生血管形成、浸润深度、分化程度及TNM分期具有相关性。本文旨在通过对CD133分子在胃癌组织中的特异性表达及其与胃癌发生发展和临床病理特征关系的进一步认识,以期为胃癌的早期诊断和靶向治疗带来新的研究方向。 The morbidity and mortality of gastric cancer stand in the first place among all kinds of malignant tumours in our country, the early diagnosis rate is still very low and the prognosis is unsatisfactory also. The expression of CD133 probably as a tumour stem cell marker is significantly higher in gastric cancer primary lesion than that in normal tissue and its higher expression corelates with the larger size of tumor, lymph node metastasis occurences and poorer prognosis. Meanwhile, the positive expression of CD133 may have some relationship with the angiogenesis, severer infiltration depth, worse differentiation degree and later TNM stage of gastric cancer. This paper aims at further recongnizing the specific expression of CD133 in gastric cancer primary lesion, both the relationship with initiating and clinical pathological features of gastric cancer, so as to bring a new research direction for early diagnosis and targeted therapy of stomach cancer.
出处 《国际外科学杂志》 2012年第1期56-59,共4页 International Journal of Surgery
关键词 CD133 血管生成 胃癌 CD133 Angiogenesis Gastric neoplasm
  • 相关文献

参考文献4

二级参考文献44

  • 1Hambardzumyan D,Squartro M,Holland EC.Radiation resistance and stem-like cells in brain tumors[J].中国神经肿瘤杂志,2006,4(4). 被引量:34
  • 2San W, Hailer DG. Recent advances in the treatment of gastriccancer [J]. Drug, 2001,61(11): 1545-1551.
  • 3D' Ugo D, Persiani R, Pende V, et al. Neoadjuvant chemotherapy in gastric carcinoma[J]. Ann Ital Chir, 2001, 72( 1 ) : 47.
  • 4Zori Comba A, Blajiman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5 - fluorouracil and folinic acid (Mayo clinic regimen) in previously untreated meta2 static colorectal cancer patients [ J ]. Eur J Cancer, 2001, 37(8): 1006-1013.
  • 5Macdomald JS. Clinical overview : adjuvant therapy of gastrointestinal cancer [ J ]. Cancer Chemother Pharmacol, 2004, 54 Suppl : s4.
  • 6Persiani R, D' Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D22 gastrectomy [ J]. J Surg Oncol, 2005, 89 (4) : 227-236.
  • 7Yoshida H, Ishiko O, Sumi T, et al. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell and serous- type ovarian carcinomas [J]. Int J Oncol, 2001, 19(3) : 537.
  • 8Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherarpy and preopeartive chemoiadrothearpy on operative morbidity and mortality inpatients with locoregional aden ocarcinoma of the stomach or gastroesphageal junction [ J ]. Ann Surg Oncol, 2007, 14(7) : 2010-2017.
  • 9Kondo T;Setoguchi T;Tags T.Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line,2004(03).
  • 10Yin AH;Miraglia S;Zanjani ED.AC133, a novel marker for human hematopoietic stem and progenitor cells,1997.

共引文献89

同被引文献121

引证文献7

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部